160 related articles for article (PubMed ID: 11594775)
1. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer.
Okada N; Ishida H; Murata N; Hashimoto D; Seyama Y; Kubota S
Biochem Biophys Res Commun; 2001 Oct; 288(1):212-6. PubMed ID: 11594775
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.
Waas ET; Wobbes T; Lomme RM; DeGroot J; Ruers T; Hendriks T
Br J Surg; 2003 Dec; 90(12):1556-64. PubMed ID: 14648736
[TBL] [Abstract][Full Text] [Related]
3. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
7. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach.
Ogawa M; Ikeuchi K; Watanabe M; Etoh K; Kobayashi T; Takao Y; Anazawa S; Yamazaki Y
Hepatogastroenterology; 2005; 52(63):875-80. PubMed ID: 15966224
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer.
Patel BP; Shah SV; Shukla SN; Shah PM; Patel PS
Head Neck; 2007 Jun; 29(6):564-72. PubMed ID: 17252594
[TBL] [Abstract][Full Text] [Related]
10. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
12. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
13. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Inuzuka K; Ogata Y; Nagase H; Shirouzu K
J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
[TBL] [Abstract][Full Text] [Related]
14. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
[TBL] [Abstract][Full Text] [Related]
15. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
16. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.
Lubbe WJ; Zhou ZY; Fu W; Zuzga D; Schulz S; Fridman R; Muschel RJ; Waldman SA; Pitari GM
Clin Cancer Res; 2006 Mar; 12(6):1876-82. PubMed ID: 16551873
[TBL] [Abstract][Full Text] [Related]
17. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas.
Matsuyama Y; Takao S; Aikou T
J Surg Oncol; 2002 Jun; 80(2):105-10. PubMed ID: 12173379
[TBL] [Abstract][Full Text] [Related]
18. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
Bianco FJ; Gervasi DC; Tiguert R; Grignon DJ; Pontes JE; Crissman JD; Fridman R; Wood DP
Clin Cancer Res; 1998 Dec; 4(12):3011-6. PubMed ID: 9865914
[TBL] [Abstract][Full Text] [Related]
20. Measuring gelatinase activity in colorectal cancer.
Baker EA; Leaper DJ
Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
